In this issue:
Environmental risk factors for GPA in NZ
TIQ-20: a tophus-specific PRO for tophaceous gout
Clinical markers predict SSc disease progression
Tofacitinib promising in RA failing to respond to DMARDs
Autoantibody profiles in the Waikato (NZ) SSc cohort
Allopurinol for gout: no increased mortality risk
Allopurinol dose-titration strategy well tolerated
Classification criteria for gout in early and established disease
Long-term safety of rituximab in RA
Celecoxib vs chondroitin+glucosamine in painful knee OA
Please login below to download this issue (PDF)